HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Published online before print April 7, 2006

This Article Full Text Full Text (PDF) All Versions of this Article: jlb.1105623v1 79/6/1157    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Alfonso-Pérez, M. Articles by Muñoz, C. Search for Related Content PubMed PubMed Citation Articles by Alfonso-Pérez, M. Articles by Muñoz, C.

(Journal of Leukocyte Biology. 2006;79:1157-1165.)
© 2006 by Society for Leukocyte Biology

Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia

Manuel Alfonso-Pérez^*, Sonia López-Giral^*, Nuria E. Quintana^*, Javier Loscertales, Patricia Martín-Jiménez and Cecilia Muñoz^*,1

^* Departments of Immunology and
Hematology, Hospital Universitario de La Princesa, Madrid, Spain; and
Department of Hematology, Hospital Clínico Universitario de Salamanca, Spain

¹Correspondence: Servicio de Inmunología, Hospital Universitario de La Princesa, C/Diego de León 62, 28006 Madrid, Spain. E-mail: cmunoz.hlpr{at}salud.madrid.org

ABSTRACT

To date, chronic lymphocytic leukemia (CLL) remains incurable with current treatments, which include the monoclonal antibodies (mAbs) rituximab and alemtuzumab. The efficacy of rituximab is modest when used as single agent, and alemtuzumab induces severe immunosuppression. To develop more potent and specific therapies, we propose the CC chemokine receptor 7 (CCR7) as an attractive target molecule to treat CLL, as it not only fulfills the requirements of a high-surface expression and a good level of tissue specificity, but it also plays a crucial role in mediating the migration of the tumor cells to lymph nodes (LNs) and thus, in the development of clinical lymphadenopathy. In the current work, murine anti-human CCR7 mAb mediated a potent, complement-dependent cytotoxicity (CDC) against CLL cells while sparing normal T lymphocytes from the same patients. The sensitivity to CDC was related to the antigenic density of CCR7. Moreover, these mAb blocked the in vitro migration of CLL cells in response to CC chemokine ligand 19 (CC219), one of the physiological ligands of CCR7. Conversely, CLL cells were poorly lysed through antibody-dependent, cell-mediated cytotoxicity (ADCC), probably as a result of the murine origin and the isotype of the anti-CCR7 mAb used. Molecular engineering techniques will allow us to obtain chimeric or humanized anti-CCR7 mAb to reach the best clinical response for this common and yet incurable leukemia.

Key Words: immunotherapy • chemokines • cytotoxicity • metastasis • chemotaxis • tumor

This article has been cited by other articles:

				M. C. Picchio, E. Scala, D. Pomponi, E. Caprini, M. Frontani, I. Angelucci, A. Mangoni, C. Lazzeri, M. Perez, D. Remotti, et al. CXCL13 Is Highly Produced by Sezary Cells and Enhances Their Migratory Ability via a Synergistic Mechanism Involving CCL19 and CCL21 Chemokines Cancer Res., September 1, 2008; 68(17): 7137 - 7146. [Abstract] [Full Text] [PDF]

				J. Redondo-Munoz, M. Jose Terol, J. A. Garcia-Marco, and A. Garcia-Pardo Matrix metalloproteinase-9 is up-regulated by CCL21/CCR7 interaction via extracellular signal-regulated kinase-1/2 signaling and is involved in CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and migration Blood, January 1, 2008; 111(1): 383 - 386. [Abstract] [Full Text] [PDF]

				E. Ziegler, M. Oberbarnscheidt, S. Bulfone-Paus, R. Forster, U. Kunzendorf, and S. Krautwald CCR7 Signaling Inhibits T Cell Proliferation J. Immunol., November 15, 2007; 179(10): 6485 - 6493. [Abstract] [Full Text] [PDF]